This regulation provides formula compound (1),They are catalphamine prophets for the treatment of diseases and neurodegenerative disorders This document also provides pharmaceutical ingredients, including synthetic drugs, and methods for the treatment of neurodegenerative or neuropsychiatric disorders and disorders using existing compounds, particularly Parkinson's disease. 2. Therefore, in the formula compound (2) of the application, R1 is h and R2, which is selected from the substitutes of formulas (3) and (4) listed below； or R1 is selected from the alternatives of formulas (3) and (4) listed below, where R2 is h；O r 1 and R 2 are represented by the following formula substitutes； or R 1 and R 2 are represented by the following formula substitutes； or R 1 and R 2 are represented by the following formula substitutes； or R 1 alternative formula alternatives (3) and R 2 alternative formula substitutes (4)； and；O R1 is the substitute of formula (4)； R2 is the substitute of formula (3)；Where * denotes the connection point； the carbon atom of the binding point in formula substitute (3) is in the s configuration； or it is a pharmaceutically acceptable salt.La presente proporciona compuestos de fórmula (1), que son profármacos de catecolamina para uso en el tratamiento de enfermedades y trastornos neurodegenerativos. La presente proporciona también composiciones farmacéuticas que comprenden compuestos de la misma y métodos de tratar enfermedades y trastornos neurodegenerativos o neuropsiquiátricos utilizando los compuestos de la presente, en particular la enfermedad de Parkinson. Por consiguiente, la presente se refiere a compuestos de fórmula (2) donde R¹ es H y R² se selecciona de uno de los sustituyentes de fórmula (3) y (4) que figuran más adelante； o R¹ se selecciona de uno de los sustituyentes de fórmula (3) y (4) que figuran más adelante y R² es H； o R¹ y R² se representan ambos por el sustituyente de fórmula (3) que figura más adelante； o R¹ y R² se representan am
